Clearmind Medicine, a clinical-stage psychedelic pharmaceutical company, has entered a development agreement with Polyrizon to advance an intranasal formulation of MEAI, its proprietary non-hallucinogenic neuroplastogen designed for treating addiction-related disorders, weight loss, and other central nervous system conditions.
Under the agreement, Polyrizon will apply its proprietary intranasal hydrogel technology to develop an optimized formulation of MEAI (5-methoxy-2-aminoindane). This strategic collaboration integrates Clearmind’s expertise in non-hallucinogenic neuroplastogens with Polyrizon’s specialized intranasal delivery platform. The objective is to create a novel intranasal MEAI formulation that will support Clearmind’s ongoing and future clinical development programs.
The intranasal approach offers distinct advantages over traditional oral routes. These include enhanced nasal residence time via specialized gel-like mechanisms that potentially improve bioavailability and duration of effect, targeted delivery of MEAI to improve therapeutic outcomes, optimized patient usability, and formulation flexibility adapted to MEAI’s physicochemical properties. Intranasal administration bypasses first-pass metabolism for more direct systemic and central nervous system access, provides faster onset of absorption, and enables lower effective doses.
Clearmind Medicine, trading on Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0,” is focused on the discovery and development of novel psychedelic-derived therapeutics to address widespread and underserved health problems, including alcohol use disorder. The company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents, and the company intends to seek additional patents for its compounds whenever warranted while remaining opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/02/g50442346/clearmind-medicine-enters-into-development-agreement-to-advance-intranasal-formulation-for-its-pro